Increasing prevalence of self-reported HIV pre-exposure prophylaxis (PrEP) use in published surveys – A systematic review and meta-analysis

: When combining results from all published surveys, about one in nine global study participants (10.7%) reported ever using PrEP by 2017, a significant increase since U.S. FDA approval in 2012 (OR = 1.6/year, p < 0.00001). Moreover, nearly one in six US-based study participants (17.3%) and nearly one in four MSM who met the CDC's PrEP indications (24.5%) reported ever using PrEP by 2016. The odds of reporting PrEP use are approximately doubling each year (OR = 1.8/year, p < 0.00001; OR = 2.0/year, p < 0.00001)

• Population(s)
  • General HIV- population
• Prevention
  • Biomedical interventions